Cellomics Inc., a business unit within Thermo Fisher Scientific, is headquartered in Pittsburgh, PA USA and provides complete systems for High Content Screening (HCS) and Analysis (HCA). Cellomics combines the high information content that fluorescence imaging provides with the automated analysis and data storage that robust assays demand. Cellomics platforms are used in pharmaceutical, biotechnology, and academic laboratories throughout the world.
The unique technology pioneered by Cellomics in the 1990's integrates HCS instrumentation (both fixed and end-point and kinetic systems), image analysis modules, multi-parametric assays, validated reagents and informatic tools to achieve a flexible, broadly applicable platform for users. Cellomics has a direct impact in every segment of drug discovery from target identification through in vitro toxicology, as well as in all areas of basic research including cellular and systems biology.
The Cellomics platform includes automated imaging instrumentation (ArrayScan® HCS Readers), BioApplication image analysis software, High Content Informatics (HCi™), and HitKit® HCS Reagent Kits, fully integrated to improve the quality and productivity of cell-based assays.
Cellomics now sold as a part of Thermo Fisher Scientific.
